Global Blood Therapeutics said Wednesday that an experimental therapy for sickle cell disease achieved its primary goal in the first stage of a Phase 3 clinical trial, an encouraging development both for the company and for patients who sorely need new treatment options.
But Global Blood also threw a risky, regulatory curveball into its announcement about the drug, known as voxelotor.
About the Author Reprints
